Skip Navigation

Profile

Jimmy Ruiz, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

32 Ratings
4 Comments
 

Jimmy Ruiz, M.D.

Associate Professor,

Clinical Interests

Lung Cancer, Thoracic Cancer

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Additional Languages

Spanish

Education & Training

  • M.D., Southern Illinois University-Carbondale, 2004
  • Residency, Internal Medicine, NC Baptist Hospital, 2005
  • Internship, Internal Medicine, NC Baptist Hospital, 2007
  • Fellowship, Hematology And Oncology, WFU School of Medicine, 2011

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology

NPI Number

  • 1265494413
Jimmy Ruiz, M.D.

Doctor Rating

4.7 out of 5

32 Ratings
4 Comments
 

Jimmy Ruiz, M.D.

Associate Professor, Hematology & Oncology

Research Interests

Brain Neoplasms; Lung Neoplasms; Glioma; Antineoplastic Agents; Small Cell Lung Carcinoma
More »

Contact Information

Academic: 336-716-0230 | Department: 336-716-4464

Recent Publications

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1 [letter]. Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W... Mol Cancer. 2018;17(1):81.

Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes?. Soike MH, McTyre ER, Hughes RT, Farris M, Cramer CK, LeCompte MC, Lanier CM, Ruiz J, Su J, Watabe K, Bourland JD, Munley MT, O'Neill S, Laxton AW, Tatter SB, Chan MD.. J Neurooncol. 2018;():.

Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery. McKay WH, McTyre ER, Okoukoni C, Alphonse-Sullivan NK, Ruiz J, Munley MT, Qasem S, Lo HW, Xing F, Laxton AW, Tatter SB, Watabe K, Chan MD.. J Neurosurg. 2017;127(1):148-156.

Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. McTyre ER, Johnson AG, Ruiz J, Isom S, Lucas JT Jr, Hinson WH, Watabe K, Laxton AW, Tatter SB, Chan MD.. Neuro Oncol. 2017;19(4):558-566.

The effects of smoking status and smoking history on patients with brain metastases from lung cancer. Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD.. Cancer Med. 2017;6(5):944-952.

Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. Ayala-Peacock DN, Attia A, Braunstein SE, Ahluwalia MS, Hepel J, Chung C, Contessa J, McTyre E, Peiffer AM, Lucas JT Jr, Isom S, Pajewski NM, Kotecha R, Stavas MJ, Page BR, Kleinberg L, Shen C, Taylor RB, Onyeuku NE, Hyde AT, Gorovets D,.. J Neurooncol. 2017;135(2):403-411.

Stereotactic radiosurgery in the treatment of brain metastases from gynecologic primary cancer. Johnston H, McTyre ER, Cramer CK, Lesser GJ, Ruiz J, Bourland JD, Watabe K, Lo HW, Qasem S, Laxton AW, Tatter SB, Chan MD.. J Radiosurg SBRT. 2017;5(1):55-61.

Staged stereotactic radiosurgery for large brain metastases: local control and clinical outcomes of a one-two punch technique. Dohm A, McTyre ER, Okoukoni C, Henson A, Cramer CK, LeCompte MC, Ruiz J, Munley MT, Qasem S, Lo HW, Xing F, Watabe K, Laxton AW, Tatter SB, Chan MD.. Neurosurgery. 2017;():.

Clinical outcomes of upfront stereotactic radiosurgery alone for patients with greater than 4 brain metastases [abstract]. Hughes RT, McTyre E, LeCompte MC, Cramer CK, Munley MT, Laxton A, Tatter SB, Ruiz J, Pasche B, Watabe K, Chan MD.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E80-E81.

Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery [abstract]. McTyre E, Farris M, Ayala-Peacock DN, Page BR, Shen C, Kleinberg LR, Contessa JN, Chung C, Ruiz J, Pasche B, Watabe K, Fiveash JB, Hepel JT, Chao ST, Braunstein SE, Attia A, Chan MD.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E93.

Drivers of the cost of management in patients treated with radiosurgery without whole brain radiation therapy for brain metastases [abstract]. Shenker RF, McTyre E, Cramer CK, Munley MT, Ruiz J, Watabe K, Pasche B, Laxton A, Tatter SB, Chan MD.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E414-E415.

Determination of tumor gene expression in non-small cell lung cancer patients who develop brain metastasis diagnosis: analysis of a prospective trial [abstract]. Dohm AE, Su J, McTyre E, Soike M, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow L, Watabe K, Chan MD, Ruiz J, Pasche B.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E453.

Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes? [abstract]. Soike M, McTyre E, Farris M, Hughes RT, Cramer CK, LeCompte MC, Ruiz J, Bourland JD, Munley MT, Laxton A, Tatter SB, Chan MD.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):S170.

Results of a phase 2 study of consolidative thoracic radiotherapy and/or stereotactic body radiotherapy for oligometastatic NSCLC [abstract]. Hughes RT, Ahmed T, Urbanic JJ, D'Agostino R, Dothard A, Lally BE, Ruiz J, Hinson W, Bonomi M, Rusthoven KE, Petty WJ, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):S212.

Sociodemographic predictors of patients with brain metastases treated with stereotactic radiosurgery. Alphonse-Sullivan N, Taksler GB, Lycan T, Weaver KE, McTyre ER, Shenker RF, Page BR, Isom S, Johnson A, Munley MT, Laxton AW, Tatter SB, Watabe K, Chan MD, Ruiz J.. Oncotarget. 2017;8(60):101055-11.

The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: results of a large single institution retrospective analysis. Lanier CM, McTyre E, LeCompte M, Cramer CK, Hughes R, Watabe K, Lo HW, O'Neill S, Munley MT, Laxton AW, Tatter SB, Ruiz J, Chan MD.. Clin Neurol Neurosurg. 2017;165():24-28.

Survival and failure outcomes predicted by brain metastasis volumetric kinetics in melanoma patients following upfront treatment with stereotactic radiosurgery alone. LeCompte MC, McTyre E, Henson A, Farris M, Okoukoni C, Cramer CK, Triozzi P, Ruiz J, Watabe K, Lo HW, Munley MT, Laxton AW, Tatter SB, Zhou X, Chan M.. Cureus. 2017;9(12):e1934.

Recent advances in radiosurgical management of brain metastases. Devoid HM, McTyre ER, Page BR, Metheny-Barlow L, Ruiz J, Chan MD.. Front Biosci (Schol Ed). 2016;8():203-214.

Treatment of brain metastases of lung cancer in the era of precision medicine. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.. Front Biosci (Elite Ed). 2016;8():219-232.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Negative predictive value of granulomas on EBUS-TBNA in suspected extrathoracic malignancy. Bellinger CR, Sharma D, Ruiz J, Parks G, Dotson T, Haponik EF.. Lung. 2016;194(3):387-391.

Brain metastasis velocity: a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after upfront radiosurgery alone for brain metastases [abstract]. Farris M, McTyre E, Hughes RT, Ayala-Peacock DN, Randolph DM II, Bourland JD, Tatter SB, Laxton AW, Watabe K, Ruiz J, Li W, Zhou X, Chan MD.. Int J Radiat Oncol Biol Phys. 2016;96(2 Suppl):S180.

A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.. PLoS One. 2016;11(10):e0164244.

Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm. Hughes RT, Black PJ, Page BR, Lucas JT, Qasem SA, Watabe K, Ruiz J, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Radiosurg SBRT. 2016;4(2):89-96.

Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer? [editorial]. Ruiz J, Petty WJ.. Ann Transl Med. 2015;3(3):31.

Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD.. Oncotarget. 2015;6(22):18945-55.

A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers [abstract]. Gutierrez M, Giaccone G, Harper HD, Liu SV, Fang B, Ruiz J, Hinson JM, Orlemans EO, Drilon AE.. J Clin Oncol. 2015;33(15 Suppl):e19033.

Non-small cell lung cancer molecular genetic yield with small volume samples [abstract]. Bellinger C, Dotson T, Ruiz J.. Chest. 2015;148(4 Suppl):558A.

Molecular subtyping in advanced non-small cell lung cancer, a minimally invasive strategy with small volume fine needle aspirates [abstract]. Hansen K, Miller L, Dotson T, Bellinger C, Parks G, Cappellari J, Clark H, Howard C, Bolemon B, Petty WJ, Craddock L, Ruiz J.. J Thorac Oncol. 2015;10(9 Suppl 2):S701.

A competing risks analysis assessing predictors of neurologic and non-neurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy [abstract]. McTyre E, Johnson A, Ruiz J, Isom S, Lucas JT Jr, Hinson W, Watabe K, Laxton AW, Tatter SB, Chan MD.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):S176.

Impact of socioeconomic status on brain metastasis outcomes at a large academic radiosurgery center [abstract]. Houseknecht K, Taksler GB, Johnson A, Page BR, Hinson W, Laxton AW, Tatter SB, Weaver KE, Chan MD, Ruiz J.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):E366.

Growing a thoracic oncology program [abstract]. Bellinger CR, Hovda J, Petty WJ, Ruiz J, Dotson TL, Wudel LJ.. Am J Respir Crit Care Med. 2015;191():A5086.

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD.. Genome Biol. 2013;14(4):R34.

A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. Ruiz J, Case D, Enevold G, Rosdhal R, Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG, Lesser GJ.. J Neurooncol. 2012;106(3):611-617.

Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD.. J Clin Oncol. 2011;29(Suppl):e21027.

A comprehensive 3-year internal medicine residency research curriculum. Ruiz J, Wallace EL, Miller DP, Loeser RF, Miles M, DuBose TD, Lichstein PR.. Am J Med. 2011;124(5):469-473.

A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD.. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

Low-grade gliomas. Ruiz J, Lesser GJ.. Curr Treat Options Oncol. 2009;10(3-4):231-242.

Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J.. Eur J Haematol. 2008;81(4):311-316.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Lung Cancer, Thoracic Cancer
Jimmy Ruiz, M.D.

Jimmy Ruiz, M.D.

Associate Professor, Hematology & Oncology

Doctor Rating

4.7 out of 5

Jimmy Ruiz, M.D.32 Ratings
4 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.7
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.7
Wait time at clinic
4.0



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

5/10/2018

Very good.

12/4/2017

Completely thorough about treatments and course of future treatments & testing.

11/26/2017

good

8/24/2017

No bad.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.